SCHEMBL4086644

SCHEMBL4086644

Nc1nc(Sc2ccccc2N)nc(-c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.49
HTR2B P41595 1/20 0.46
PDE4D Q08499 1/20 0.46
HSP90AB1 P08238 3/20 0.43
PDE7A Q13946 2/20 0.40
CDK9 P50750 1/20 0.39
ALDH1A1 P00352 3/20 0.39
PKM P14618 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 1/20 0.38
DPP4 P27487 3/20 0.37
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTPN1 P18031 1/20 0.37
CYP3A4 P08684 1/20 0.37
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097216 0.84 DPP4 (0.48) HSP90AA1HTR2BPDE4DHSP90AB1ALDH1A1
SCHEMBL6314405 0.78 HSP90AA1 (0.68) HSP90AA1HTR2BPDE4DHSP90AB1ALDH1A1
SCHEMBL9566485 0.77 HTR2B (0.72) HSP90AA1HTR2BPDE4DHSP90AB1CDK9
SCHEMBL4091773 0.76 HSP90AA1 (0.52) HSP90AA1HTR2BPDE4DHSP90AB1CDK9
SCHEMBL4096143 0.76 NPC1 (0.47) HSP90AA1HSP90AB1ALDH1A1DPP4NPC1
SCHEMBL1341957 0.71 ITGB2 (0.62) PDE7AALDH1A1PKMMAPTCYP3A4
SCHEMBL4086070 0.66 HSP90AA1 (1.00) HSP90AA1HTR2BPDE4DHSP90AB1ALDH1A1
SCHEMBL397076 0.65 ALDH1A1 (0.54) HSP90AA1HSP90AB1ALDH1A1KDM4EDPP4
SCHEMBL15101631 0.65 HSP90AA1 (0.39) HSP90AA1HSP90AB1PDE7AALDH1A1PKM
SCHEMBL2854136 0.65 HSP90AA1 (0.41) HSP90AA1HTR2BPDE4DCDK9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036895-B9 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-07-10 EP claimed
EP-2036895-B1 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-16 EP claimed
US-20090247524-A1 HSP90 Inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-10-01 US claimed
EP-2036895-A1 HSP90 INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-03-18 EP claimed
EP-2036895-B9 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-07-10 EP disclosed
EP-2036895-B9 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-07-10 EP disclosed
EP-2036895-B1 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-16 EP disclosed
EP-2036895-B1 HSP90 INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-16 EP disclosed
US-8193351-B2 HSP90 inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-05 US disclosed
US-8193351-B2 HSP90 inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-05 US disclosed
US-8193351-B2 HSP90 inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-05 US disclosed
US-20090247524-A1 HSP90 Inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-10-01 US disclosed
US-20090247524-A1 HSP90 Inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-10-01 US disclosed
US-20090247524-A1 HSP90 Inhibitor CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-10-01 US disclosed
EP-2036895-A1 HSP90 INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247524-A1 HSP90 Inhibitor HSP90AB1, HSP90B1, HSP90AA1 HSP90AA1 3/4885HTR2B 3489/4885PDE4D 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.